Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish Sells 36,081 Shares

Key Points

• Scott Lish, COO of Alphatec Holdings, Inc., sold 36,081 shares of the company on August 1st for a total transaction of $452,094.93, reducing his holdings by 4.84%.
• Alphatec reported a quarterly EPS of $0.02, beating analysts' expectations of negative earnings, with revenue reaching $185.54 million, a 27.5% increase from the previous year.
• Institutional investors currently own 66.35% of Alphatec's stock, with significant recent positioning changes from major funds like Bank of Montreal Can and Corton Capital Inc.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 36,081 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $12.53, for a total value of $452,094.93. Following the sale, the chief operating officer directly owned 708,855 shares of the company's stock, valued at approximately $8,881,953.15. This trade represents a 4.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Scott Lish also recently made the following trade(s):

• On Tuesday, August 5th, Scott Lish sold 16,666 shares of Alphatec stock. The stock was sold at an average price of $15.00, for a total value of $249,990.00.
• On Monday, August 4th, Scott Lish sold 17,857 shares of Alphatec stock. The stock was sold at an average price of $14.00, for a total value of $249,998.00.
• On Thursday, July 10th, Scott Lish sold 3,982 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total value of $47,784.00.
• On Friday, June 13th, Scott Lish sold 22,727 shares of Alphatec stock. The shares were sold at an average price of $11.07, for a total value of $251,587.89.
• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The shares were sold at an average price of $13.00, for a total value of $719,875.00.

Alphatec Stock Up 0.5%

ATEC traded up $0.07 on Friday, hitting $14.97. 1,745,343 shares of the company were exchanged, compared to its average volume of 2,816,030. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -13.25 and a beta of 1.05. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. The firm has a 50-day moving average price of $11.63 and a two-hundred day moving average price of $11.28. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $15.46.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. Alphatec's revenue for the quarter was up 27.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) EPS. On average, equities analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on ATEC. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Friday, August 1st. Barclays reissued an "overweight" rating and set a $22.00 target price (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Piper Sandler reissued an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Finally, Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 target price for the company in a research note on Monday, June 16th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Alphatec currently has a consensus rating of "Buy" and an average target price of $18.50.

Institutional Trading of Alphatec

A number of institutional investors have recently bought and sold shares of ATEC. Lido Advisors LLC raised its stake in Alphatec by 8.4% during the 4th quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company's stock valued at $112,000 after acquiring an additional 953 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock valued at $63,000 after acquiring an additional 1,045 shares during the last quarter. Oppenheimer Asset Management Inc. raised its stake in Alphatec by 8.4% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,244 shares of the medical technology company's stock valued at $158,000 after acquiring an additional 1,100 shares during the last quarter. Comerica Bank raised its stake in Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after acquiring an additional 1,248 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in Alphatec by 5.6% during the 2nd quarter. ProShare Advisors LLC now owns 23,790 shares of the medical technology company's stock valued at $264,000 after acquiring an additional 1,254 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.